# Levetiracetam for Treatment of Nonpsychotic and Non-depressive behavioural symptoms of dementia.

No registrations found.

**Ethical review** Positive opinion **Status** Recruitment stopped

Health condition type -

Study type Interventional

## **Summary**

#### ID

NL-OMON23657

Source

NTR

**Brief title** 

LaTiNN

**Health condition** 

3 moths, prospective, open label trial

### **Sponsors and support**

**Primary sponsor:** Dep geriatrics JBZ

Hervensebaan 4

Postbus 1101 5200 BD Den Bosch

073-6998629

**Source(s) of monetary or material Support:** UCB for support for statistical analysis if needed, however Dep geriatrics Utrecht University (Rob van Marum) will first performe this analysis

Maximum of € 10.000

#### Intervention

#### **Outcome measures**

#### **Primary outcome**

Effect on week 4 and 13 compared to base-line on Behauvioral symptoms (NPI and CMAI), care-giver burden (CBI) and clinical impression (GCI).

#### **Secondary outcome**

Effect on week 4 and 13 compared to base-line on cognition (MMSE) and ADL (IDDD).

## **Study description**

#### **Background summary**

N/A

#### **Study objective**

Specific behavioural symptoms of dementia needs specific treatment. In cases, Levetiracetam seems to be effective in Non-psychotic and Non-depressive behavioural symptoms of dementia.

#### Study design

N/A

#### Intervention

500 mg Levetiracetam/day, maximum 1500 mg Levetiracetam/day.

### **Contacts**

#### **Public**

Jeroen Bosch Hospital, Department Geriatrics, P.O. Box 90153

P.L.J. Dautzenberg Den Bosch 5200 ME The Netherlands +31 (0)73 6998629

2 - Levetiracetam for Treatment of Non-psychotic and Non-depressive behavioural symp ... 5-05-2025

#### **Scientific**

Jeroen Bosch Hospital, Department Geriatrics, P.O. Box 90153

P.L.J. Dautzenberg Den Bosch 5200 ME The Netherlands +31 (0)73 6998629

## **Eligibility criteria**

#### Inclusion criteria

- 1. Ambulant patients with dementia, level Reisberg 4-6;
- 2. Informant available.;
- 3. 6 weeks stable treatment of dementia; anti-psychotics and anti-depressants.

#### **Exclusion criteria**

- 1. NPI item hallucinations, delusions and depression > ;1
- 2. Epilepsia;
- 3. Alcoholism;
- 4. DM or thyroid disease not under control.

## Study design

### **Design**

Study type: Interventional

Intervention model: Other

Allocation: Non controlled trial

Masking: Open (masking not used)

Control: N/A, unknown

#### Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 01-08-2006

Enrollment: 25

Type: Actual

## **Ethics review**

Positive opinion

Date: 08-08-2006

Application type: First submission

## **Study registrations**

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

RegisterIDNTR-newNL776NTR-oldNTR787Other: N/A

ISRCTN ISRCTN97133543

## **Study results**

#### **Summary results**

Dautzenberg PLJ et al. Medicamenteuze behaneling van gedrags- en psychische problemen bij dementie (BPSD). Tijdschrift voor verpleeghuisgeneeskunde 2003;27(5):5-9. Weiner MF et al. Levetiracetam for agitated Alzheimer's disease patients. Int J Psychogeriatrics 2005;17(2):327-8.